China’s ongoing efforts to enhance its business environment are drawing significant attention from global enterprises. French pharmaceutical giant Sanofi recently demonstrated this by signing a memorandum of understanding with Beijing for an investment worth close to one billion euros (about $1.05 billion), marking the largest investment in the area in the past decade.
To understand the motivations behind this substantial investment, CGTN’s Cao Bing engaged in an exclusive interview with Sanofi Global Director and Chairman Frédéric Oudéa. The discussion aimed to uncover the factors that influenced Sanofi’s decision and what it signifies for the future of foreign companies in the Chinese mainland.
Sanofi’s investment reflects a growing confidence among foreign companies in China’s commitment to fostering a more welcoming and dynamic market environment. This development could signal a new era of collaboration and growth in the pharmaceutical sector within the Chinese mainland.
Reference(s):
What is behind pharmaceutical giant Sanofi's 1 billion euro investment in China?
cgtn.com
